| abstract |
Compounds of formula (I) and (II), pharmaceutical compositions comprising such compounds, and methods of using these compounds are disclosed as A3 adenosine receptor agonists, wherein X, Y, Z, R2 - R6 and R 103 -R 106 are as defined in the specification. These compounds are selective for the A3 receptor and are considered for use in the treatment or prevention of a number of diseases or conditions such as neuropathic pain. |